Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Deuruxolitinib is generally safe for treating alopecia areata.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

CTP-543 is generally safe for treating alopecia areata.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.

This study evaluated baricitinib 4 mg treatment in severe to very severe alopecia areata, reporting significant scalp hair regrowth by Week 52, especially in short-duration episodes, suggesting treatment should continue for at least a year before assessing failure.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study found that arachidonic acid may promote hair growth by enhancing dermal papilla cell function and stimulating the anagen phase in C57BL/6 mice.

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

This study assessed the psychosocial impact and disease burden of alopecia areata among adolescents and adults in Australia, finding substantial impacts on physical, emotional, and quality of life overall, with greater disease burden in patients experiencing more extensive hair loss.

This review synthesizes recent molecular and preclinical advances in alopecia areata and androgenetic alopecia, highlighting how interventions targeting specific intracellular signaling pathways and utilizing stem cell technologies can support precision regrowth and structural follicle reconstruction.